Abstract: A method is disclosed for obtaining affinity ligands for isolating tissue-type plasminogen activator (tPA). Ligands binding tPA with high specificity at pH 7 and releasing tPA at pH 5 or lower are disclosed.
Type:
Grant
Filed:
March 20, 1997
Date of Patent:
July 4, 2000
Assignee:
Dyax Corp.
Inventors:
John Moore Maclennan, Robert Charles Ladner, Thomas Cushman Ransohoff
Abstract: An immunogen/vaccine adjuvant composition containing an immunogen in an amount effective to stimulate an immune response and as a vaccine adjuvant a 1H-imidazo[4,5-c]quinolin-4-amine in an amount effective to increase the immune response to the immunogen.
Type:
Grant
Filed:
March 24, 1994
Date of Patent:
July 4, 2000
Assignee:
3M Innovative Properties Company
Inventors:
Richard L. Miller, Mark A. Tomai, David I. Bernstein, Christopher J. Harrison
Abstract: This invention provides a dietary supplement comprising L-Carnitine (or its functional analogues such as Acetyl-Carnitine or Proprionyl-l-Carnitine), Coenzyme Q10 and Taurine for the correction of the abnormality in mitochondrial energetics in cardiac failure and certain other diseases. A high protein nutritional feeding supplementation with Cysteine, Creatine, Vitamin E (RRR-d-alpha-tocopherol), Vitamin C (ascorbic acid), Selenium, and Thiamin in may be added.
Type:
Grant
Filed:
January 6, 1998
Date of Patent:
June 27, 2000
Inventors:
Michael J. Sole, Khursheed N. Jeejeebhoy
Abstract: The present invention is directed to novel methods for enhancing the ability to separate a species of interest from other different species present in a free solution mixture thereof which takes advantage of interactions that occur between soluble, small molecular weight ligands and the species of interest. The small molecular weight ligands employed in the present invention function to interact with a species of interest in a mixture of different species through either affinity, hydrophobic and/or ionic interactions, thereby altering the molecular weight, hydrodynamic volume and/or isoelectric point of the species of interest and rendering it separable from other component(s) in the mixture.
Abstract: The present invention is concerned with a pharmaceutical composition suitable as a depot formulation for administration via intramuscular or subcutaneous injection, comprising:(1) as an active ingredient a therapeutically effective amount of a 9-hydroxyrisperidone fatty acid ester or a salt, or a stereoisomer or a stereoisomeric mixture thereof and(2) a pharmaceutically acceptable carrier;wherein the pharmaceutically acceptable carrier is water and the active ingredient is suspended therein; and with a process of preparing such a composition. The invention further concerns such a pharmaceutical composition for use as a medicament in the treatment of schizophrenia, non-schizophrenic psychoses, behavioural disturbances associated with neurodegenerative disorders, e.g. in dementia, behavioural disturbances in mental retardation and autism, bipolar mania, depression, anxiety.
Type:
Grant
Filed:
November 12, 1998
Date of Patent:
June 20, 2000
Assignee:
Janssen Pharmaceutica, N.V.
Inventors:
Marc Karel Jozef Fran.cedilla.ois, Roger Carolus Augusta Embrechts, Herman Karel Borghijs, Johan Monbaliu
Abstract: The present invention provides a skin external preparation comprising a compound of the formula (1), (2), (3) or (4). ##STR1## wherein X represents COOH, etc., Z represents CONH.sub.2, etc. and R.sup.1 and R.sup.7 individually represent a hydrogen atom, etc.The above-described compound has excellent effects, for example, for preventing or alleviating skin aging or inhibiting hair growth.
Abstract: The present invention provides methods for preparing, and compositions comprising, stabilized protein-polymer conjugates. More particularly, the present invention relates to the stabilization of individual subunits of multisubunit protein complexes by conjugation to polymers. Such conjugation acts to stabilize the individual subunit in its native conformation in liquid medium, which in turn acts to stabilize its biological activity.
Type:
Grant
Filed:
October 15, 1997
Date of Patent:
June 6, 2000
Assignee:
Medical Analysis Systems, Inc.
Inventors:
Kirti I. Dave, Janos Botyanszki, Eva Sintar
Abstract: This invention relates to phosphotyrosine mimics which, when incorporated into an appropriate molecular structure, are capable of inhibiting the binding of tyrosine kinase-dependent regulatory proteins to the native phosphotyrosine-containing receptors. This invention also relates to methods and kits for identifying and using phosphotyrosine mimics. The compounds, kits and methods of this invention are useful for identifying and designing antagonists of tyrosine-kinase dependent regulatory proteins, such as signal transduction proteins containing SH.sub.2 binding domains.
Type:
Grant
Filed:
May 6, 1997
Date of Patent:
June 6, 2000
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc.
Abstract: Methods for obtaining beneficial stable levels of circulating histamine are disclosed for use in methods for enhancing natural killer cell cytotoxicity and for elevating histamine levels in individuals in need thereof. In such methods, a beneficial level of circulating histamine is attained and an agent whose ability to enhance natural killer cell cytotoxicity is augmented by histamine is administered. Alternatively, stable beneficial levels of circulating histamine can be attained in subjects receiving chemotherapy or antiviral treatment. The invention may also be employed in treatments combining histamine, agents which enhance natural killer cell cytotoxicity, and chemotherapeutic agents. Optimization of the delivery of histamine and substances which induce the release of endogenous histamine are also disclosed.
Type:
Grant
Filed:
November 13, 1997
Date of Patent:
June 6, 2000
Assignee:
Maxim Pharmaceuticals, Inc.
Inventors:
Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
Abstract: The present invention provides for a highly sensitive nested polymerase chain reaction (PCR) method for detecting the presence or absence of the pseudorabies virus (PVR). The method targets a 674 base-pair region of the pseudorabies virus gII gene. Nucleotide sequences for highly specific novel primers derived from this gII region are also disclosed. These primers are used with the nested polymerase chain reaction method to amplify targeted nucleotide sequences within the 674 base-pair region of the gII gene. The novel primers and optimized reaction conditions of the nested polymerase chain reaction method enable significantly greater specificity for the viral DNA in tissue suspected of harboring the latent pseudorabies virus.
Abstract: A new use of the enantiomer (R)-ketoprofen and of its salts with suitable organic and inorganic bases in the therapy of neutrophil-dependent diseases and phlogistic processes is described as well as pharmaceutical preparations containing such compounds and useful for oral, parenteral or topical administration.
Abstract: The invention relates to a drug, which contains one or more inhibitors for the cGMP-stimulated phosphodiesterase (PDE II) together with conventional substrates and/or diluents. Preferably the drug contains erythro-9-(2-hydroxy-3-nonyl)-adenine or 2-o-propoxyphenyl-8-azapurine-6-one, optionally together with one or more activators of guanyl cyclase. The invention also relates to the application of inhibitors of cGMP-stimulated phosphodiesterase (PDE II) for the control and prophylaxis of cardiovascular diseases and for the manufacture of drugs for cardiovascular diseases. Preferably erythro-9-(2-hydroxy-3-nonyl)-adenine or 2-o-propoxyphenyl-8-azapurine-6-one is used, optionally together with one or more activators of guanyl cyclase.
Abstract: Carrageenan compostions comprising from about from about 79 mol % to about 95 mol % iota carrageenan and from about 0.1 mol % to about 10 mol % nu carrageenan, and carrageenan and compositions which exhibit elastic modulus, G'--1 Hz at 5.degree. C., of greater than about 200 Pa, elastic modulus, G'--1 Hz at 25.degree. C., of less than about 200 Pa, viscous modulus, G"--0.2 Hz at 5.degree. C., of from about 5 Pa to about 25 Pa, and melting point of less than 60.degree. C., in a 1.2 wt % aqueous gel, and methods of producing the same.
Type:
Grant
Filed:
July 30, 1998
Date of Patent:
May 16, 2000
Assignee:
Hercules Incorporated
Inventors:
Jack Harbo Hansen, Jan Groendal, Henrik Larsen
Abstract: The device and methods herein disclosed were developed to allow a large number of small samples of organic tissue to be processed. The goal was to allow for the capture of these intracellular contents for study, use, and/or amplification. Though the device and specific protocols can be used to retrieve a variety of intracellular molecules one of the preferred embodiments particularly lends itself to the extraction of DNA. The electromagnetic device uses a set of terraced coils controlled in such a matter as to continually alternate polarity and thereby emulate the random motion of a manual mortal and pestle. This simulation of random motion is created through the arrangement of coils found in this invention. Methods were also developed to aid in the retrieval of DNA or other intracellular components using this device such that these components can be isolated and then used for study, amplification, or a variety of different purposes.
Type:
Grant
Filed:
November 4, 1997
Date of Patent:
May 16, 2000
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Norman F. Weeden, Dale Loomis, Joseph A. Celeste
Abstract: Neuroprotective drugs are disclosed with at least 3 branches extending outwardly from a center atom or group, each branch having a guanidino group at its terminus. All branches preferably should be identical, and distributed around the center atom or group in a radial manner. Three branches can be bonded to a nitrogen atom, or four branches can be coupled to a carbon atom; other center groups include stable aromatic, cycloalkyl, heterocyclic, or bicyclic structures. Starting reagents are disclosed with a center atom or group, and with reactive groups (such as primary amines or hydroxyl groups) at the ends of short "spacer chains" bonded to the center atom or group. Reagents derived from arginine (an amino acid having a terminal guanidino group) can be bonded to these center components, using protective groups on the arginyl reagents to ensure desired final products with accessible guanidino groups at the ends of spacer chains.
Type:
Grant
Filed:
February 18, 1998
Date of Patent:
May 16, 2000
Assignee:
Cypros Pharmaceutical Corp.
Inventors:
Paul J. Marangos, Brian W. Sullivan, Torsten Wiemann, Anne M. Danks, Marina Sragovicz, Lewis R. Makings
Abstract: The present invention provides an inexpensive and sensitive device and method for detecting and quantifying analytes present in a medium. The device comprises a metalized film upon which is printed a specific, predetermined pattern of analyte-specific receptors. Upon attachment of a target analyte to select areas of the plastic film upon which the receptor is printed, diffraction of transmitted and/or reflected light occurs via the physical dimensions and defined, precise placement of the analyte. A diffraction image is produced which can be easily seen with the eye or, optionally, with a sensing device.
Type:
Grant
Filed:
December 16, 1997
Date of Patent:
May 9, 2000
Assignee:
Kimberly-Clark Worldwide, Inc.
Inventors:
Dennis S. Everhart, Mark L. Jones, Rosann Marie Kaylor
Abstract: The present invention describes a novel treatment for movement disorders, including tardive dyskinesia and tardive dystonia, and focal dystonias not due to neuroleptics, including blepharospasm, Meige syndrome, and occupational dystonias. The treatment of the present invention utilizes agents that act as NMDA-type glutamate receptor antagonists The invention also involves the use of an ion channel blocking agent to augment the therapeutic action of the drug treatments described. A particularly preferred ion channel blocking agent is magnesium.
Abstract: The present invention provides a highly efficient method for treating substance addiction and for changing addiction-related behavior of a primate suffering from substance addiction. The method includes administering to a primate an effective amount of a pharmaceutical composition including gamma vinylGABA. The present invention also provides a method of treatment of nicotine addiction by treating a patient with an effective amount of a composition including gamma vinylGABA.
Type:
Grant
Filed:
August 5, 1998
Date of Patent:
May 2, 2000
Assignee:
Brookhaven Science Associates LLC
Inventors:
Stephen L. Dewey, Jonathan D. Brodie, Charles R. Ashby, Jr.
Abstract: The present invention relates to methods of treating gram-positive bacterial infections by administration of a BPI protein product alone, or in combination with an antibiotic. BPI protein product alone has a bactericidal or growth inhibitory effect on selected gram-positive organisms. BPI protein product also increases the susceptibility of gram-positive organisms to antibiotics and can even reverse resistance of gram-positive organisms to antibiotic.
Type:
Grant
Filed:
July 20, 1998
Date of Patent:
April 25, 2000
Assignee:
XOMA Corporation
Inventors:
Arnold Horwitz, Lewis H. Lambert, Jr., Roger G. Little, II